Section 4: Clinical Pharmacy Services

4CPS-347

CLINICAL TRIAL DRUGS: DISPENSING OPTIMISATION FOR OUTPATIENTS OF A CANCER CENTRE

4CPS-346

EVALUATION OF THE IMPLEMENTATION OF "INHALER INTERVIEWS" DURING MEDICATION RECONCILIATION IN THE PNEUMOLOGY SERVICE

4CPS-345

MANAGEMENT OF BRONCHIOLITIS IN HOSPITALISED CHILDREN

4CPS-344

PRESCRIPTION AUDITING OF THE 3 MONTHLY FORMULATION OF PALIPERIDONE PALMITATE IN ADULT PATIENTS WITH SCHIZOPHRENIA

4CPS-343

PREGABALIN AND GABAPENTIN DRUG UTILISATION REVIEW

4CPS-342

TRANSIENT VALPROIC ACID TOXICITY: HYPERAMMONAEMIA IN A PAEDIATRIC PATIENT

4CPS-340

PROFILE OF PATIENTS WITH ABUSIVE CONSUMPTION OF QUICK RELEASE FENTANYL IN A HEALTHCARE AREA

4CPS-339

INTRATHECAL ADMINISTRATION OF BACLOFEN FOR THE REDUCTION OF SPASTICITY

4CPS-338

USE AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA

4CPS-337

PERSISTENCE OF BIOSIMILAR TREATMENT FOR IMMUNE MEDIATED INFLAMMATORY DISEASES IN CLINICAL PRACTICE

4CPS-336

IMPACT OF CHECK OF MEDICATION APPROPRIATENESS (CMA) IN OPTIMISING ANALGESIC PRESCRIBING

4CPS-335

EXPERIENCE IN THE USE OF TOCILIZUMAB IN PATIENTS WITH COVID-19. HAS IT REALLY BEEN EFFECTIVE?

4CPS-334

INFLUENCE OF ANTHROPOMETRIC, DEMOGRAPHIC AND THERAPEUTIC FACTORS ON SERUM CONCENTRATIONS OF ANTI-TNF DRUGS

4CPS-333

TREATING MULTIPLE SCLEROSIS PATIENTS WITH INFUSION OF DISEASE MODIFYING TREATMENTS DRUGS DURING THE COVID-19 PANDEMIC

4CPS-332

TOCILIZUMAB FOR TREATING COVID PNEUMONIA: ANALYSIS OF EFFECTIVENESS AND SECURITY

Pages